Related Experiment Videos
[Clinical study on SM-4300 in the field of internal medicine]
Abstract:
A new human gamma-globulin for intravenous use, SM-4300, was administered to 13 patients with infectious diseases. Five grams of SM-4300 was drip infused to each patient whose infection was not controlled by previous administered antibiotics. All of 13 patients had primary diseases besides infections. Thirteen patients were composed of 4 with pyelonephritis, 2 with pneumonia, 1 with bronchopneumonia, 1 with bronchitis, 1 with pyothorax, 2 with sepsis and 2 with cholecystitis. The results obtained were good in 3 cases, fair in 2 cases and poor in 7 cases. The results of a patient was not determined. No side effect was found including in laboratory findings.
Insights
A new intravenous gamma-globulin (SM-4300) showed limited efficacy in treating severe infectious diseases unresponsive to antibiotics. While well-tolerated with no observed side effects, further research is needed to determine its therapeutic potential.
Area of Science:
- Immunology
- Infectious Diseases
- Pharmacology
Background:
- Severe infectious diseases often present challenges for antibiotic therapy.
- Intravenous gamma-globulin is explored as an adjunctive treatment for various conditions.
- Limited data exists on novel gamma-globulin formulations like SM-4300 for complex infections.
Purpose of the Study:
- To evaluate the clinical efficacy and safety of a new human gamma-globulin, SM-4300, for intravenous use.
- To assess SM-4300 in patients with infectious diseases refractory to conventional antibiotic treatment.
- To determine the effectiveness of SM-4300 across a spectrum of serious infections.
Main Methods:
- A total of 13 patients with infectious diseases were enrolled.
- Each patient received a 5-gram dose of SM-4300 via drip infusion.
- Patients had primary diseases and infections not controlled by prior antibiotic therapy.
Main Results:
- Overall efficacy was rated as good in 3 patients, fair in 2, and poor in 7.
- The outcome for one patient could not be determined.
- No adverse events or laboratory abnormalities were reported during the study.
Conclusions:
- SM-4300 demonstrated a poor to fair response in the majority of patients with severe infections.
- The new gamma-globulin preparation was found to be safe and well-tolerated.
- Further investigation is warranted to explore SM-4300's role in managing infectious diseases.